Connecting the dots...Provectus Biopharmaceuticals

Certain brokers called certain Provectus shareholders late last week -- that is, the brokerage firms (or "brokers") where these ...

If you write, like I did , "PV-10, a novel oncology compound, exemplifies innovation over incrementalism, meaningful over marginal, pro...

I read through Provectus' recent  3rd quarter 2013 10-Q filing  (filed on November 12th) and prospectus supplement  (November 12th). T...

Among several aspects of the Provectus story I detailed in my post  Expect More , one was the evolution of the parameters of the pivotal Pha...

In Provectus' annual CEO letter published May 2013 , management wrote under Regulatory Progress: "Provectus is finalizing detai...

wait·ing [wey-ting] For management... When will Provectus principals complete the management of the regulatory approval process ...

Whisper numbers, on Wall Street, are the "unofficial and unpublished earnings per share forecasts of companies that circulate among pro...